Compare PRVA & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRVA | VERA |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.2B |
| IPO Year | 2021 | 2021 |
| Metric | PRVA | VERA |
|---|---|---|
| Price | $24.75 | $35.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | $31.17 | ★ $81.30 |
| AVG Volume (30 Days) | 718.7K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.64 | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $2,122,842,000.00 | N/A |
| Revenue This Year | $18.19 | N/A |
| Revenue Next Year | $10.72 | $472.48 |
| P/E Ratio | $138.06 | ★ N/A |
| Revenue Growth | ★ 22.26 | N/A |
| 52 Week Low | $18.78 | $18.76 |
| 52 Week High | $26.51 | $56.05 |
| Indicator | PRVA | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 66.49 | 30.97 |
| Support Level | $22.63 | $22.10 |
| Resistance Level | $25.23 | $42.77 |
| Average True Range (ATR) | 0.73 | 1.88 |
| MACD | 0.13 | -0.68 |
| Stochastic Oscillator | 81.98 | 5.44 |
Privia Health Group Inc is one of the physician enablement companies in the United States with a presence in around 24 states and the District of Columbia. The group builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. It collaborates with medical groups, health plans, and health systems to optimize approximately 1,300+ physician practices, improve the patient experience for over 5.8+ million patients, and reward around 5,300+ physicians and practitioners for delivering high-value care.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.